Rectal CarcinomaNCT07363863
Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma
An observational study of Rectal Carcinoma, run by Sohag University.
Trial summary
the study will discuss different pattern of treatment and the outcomes of locally advanced rectal carcinoma as a retrospective study. The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Rectal Carcinoma
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to 1 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
Who may be able to join
- patients who were more than18 years old at time of diagnosis.
- Patients with histologically confirmed rectal carcinoma.
- Stage II-III (locally advanced) disease at initial diagnosis.
Who cannot join
- Patients with distant metastasis at presentation.
- Patients diagnosed with double malignancy.
- Patients with incomplete medical records.
- Organ failure
About this study
Official title: Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma : a Retrospective Study
the study will discuss different pattern of treatment and the outcomes of locally advanced rectal carcinoma as a retrospective study.
The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
including patients diagnosed and treated between 2018 and 2025. and the data will be collected from reports .
- Conditions
- Rectal Carcinoma
- Being tested
- No Intervention (subjects were previously treated with Onglyza®)
- Medical subject headings
- Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention (subjects were previously treated with Onglyza®)Other
no intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Estimation of overall survival (OS ).
Measured: 2018 _ 2025
Estimation of Response rate .
Measured: 2018-2025
Estimation of disease-free survival (DFS) .
Measured: 2018-2025
Secondary outcomes (1)
treatment-related toxicity: (graded by CTCAE v5).
Measured: 2018-2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start1 Mar 2026 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rectal CarcinomaStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Azhar Abdelgaber Moez Abdelraheem, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07363863
- Sponsor's protocol ID
- Soh-Med--25-11-2MS
- Status last verified
- Nov 2025
- First submitted
- 27 Nov 2025
- Last updated
- 23 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma : a Retrospective Study
- ClinicalTrials.gov ID
- NCT07363863
- Acronym / sponsor ID
- Soh-Med--25-11-2MS
- Conditions
- Rectal Carcinoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Oct 2026 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the study will discuss different pattern of treatment and the outcomes of locally advanced rectal carcinoma as a retrospective study.
The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
including patients diagnosed and treated between 2018 and 2025. and the data will be collected from reports .
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
Key inclusion criteria (3 listed)
- patients who were more than18 years old at time of diagnosis.
- Patients with histologically confirmed rectal carcinoma.
- Stage II-III (locally advanced) disease at initial diagnosis.
Key exclusion criteria (4 listed)
- Patients with distant metastasis at presentation.
- Patients diagnosed with double malignancy.
- Patients with incomplete medical records.
- Organ failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention (subjects were previously treated with Onglyza®)no intervention | Other | – |
Primary outcome
Estimation of overall survival (OS ).
Time frame: 2018 _ 2025
Estimation of Response rate .
Time frame: 2018-2025
Estimation of disease-free survival (DFS) .
Time frame: 2018-2025
1 secondary outcome
treatment-related toxicity: (graded by CTCAE v5).
Time frame: 2018-2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2026.
Related trials for Rectal Carcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Not yet recruitingObservational study
Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment
Rectal Cancer, Chemoradiotherapy
RecruitingObservational study
Outcomes of Knife-Assisted Full-Thickness Resection for Rectal Lesions: A Multicenter Study
Colorectal Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Rectal Carcinoma, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Estimation of overall survival (OS ). (time frame: 2018 _ 2025). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.